article thumbnail

As Viatris seeks growth in eye care, its Ocuphire-partnered dilation drop Ryzumvi wins FDA nod

Fierce Pharma

The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The partners plan to make Ryzumvi available in the U.S.

article thumbnail

Mastering Pharmacology: A Game-Changer for Pharma Sales Reps Communicating with HCPs

Pharmaceutical Representative Training

Pharmacology is one of the most fundamental aspects of medication therapy. 1] How can mastering pharmacology give sales reps a competitive advantage when meeting with prospective HCPs? Due to limited knowledge of pharmacology, the sales rep failed to properly communicate and was unable to address the physicians concerns.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Navigating Pharma Sales Challenges: Tips to Boost Your Sales Performance (Use of AI and Social Media for Effective brand promotion)

Pharmaceutical Representative Training

The Evolution of Pharma Sales: Combining AI and Social Media to Promote Brands Pharmaceutical businesses now have access to a whole new level of insights due to social media. 1] The Challenges Pharma Sales Teams Face Teams encounter certain challenges that reduce the efficacy of conventional approaches.

Media 52
article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

Supply Chain Management Due to geopolitical and climate-related challenges , Pharma supply chain disruptions are becoming increasingly common and complex. To avoid compliance issues , it is essential to keep up with new regulatory changes, including updated reporting guidelines and safety requirements.

Pharma 92
article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

There is a clear trend away from developing pharmacological therapies targeting opioid receptors” There is a clear trend away from developing pharmacological therapies targeting opioid receptors. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience. References Cruccu G, Truini A.

Medicine 102
article thumbnail

Viatris, Ocuphire Pharma Receive FDA Approval on Ryzumvi

PharmExec

Eye drop treatment indicated for pharmacologically induced mydriasis.

article thumbnail

invoX Pharma agrees to acquire biopharma firm F-star Therapeutics for $161m

Pharmaceutical Technology

invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. for each share in cash.